What is the recommended management for deep vein thrombosis?

Management of Deep Vein Thrombosis

For acute DVT, initiate anticoagulation immediately with a direct oral anticoagulant (DOAC) such as apixaban or rivaroxaban as monotherapy, or use low-molecular-weight heparin (LMWH) bridged to dabigatran/edoxaban, and continue therapeutic anticoagulation for a minimum of 3 months. 1, 2

Initial Anticoagulation Strategy

First-Line Therapy: Direct Oral Anticoagulants (DOACs)

DOACs are strongly preferred over warfarin for DVT treatment due to superior safety, equal efficacy, and greater convenience. 1, 3, 2

Specific DOAC regimens:

• Apixaban: 10 mg orally twice daily for 7 days, then 5 mg twice daily (no parenteral lead-in required) 4, 2
• Rivaroxaban: 15 mg orally twice daily for 21 days, then 20 mg once daily (no parenteral lead-in required) 5, 4, 2
• Dabigatran: Requires 5-10 days of parenteral anticoagulation (LMWH or fondaparinux) first, then 150 mg orally twice daily 1, 6
• Edoxaban: Requires at least 5 days of parenteral anticoagulation first, then 60 mg once daily (30 mg if creatinine clearance 30-50 mL/min or weight <60 kg) 4, 6

Alternative: LMWH with Warfarin Bridge

If DOACs are contraindicated (severe renal impairment with CrCl <30 mL/min, pregnancy, antiphospholipid syndrome), use LMWH bridged to warfarin: 1, 6, 2

• Enoxaparin: 1 mg/kg subcutaneously every 12 hours OR 1.5 mg/kg once daily 5, 4
• Dalteparin: 200 units/kg subcutaneously once daily 7, 4
• Start warfarin on day 1 alongside parenteral therapy, continue both for minimum 5 days AND until INR ≥2.0 for at least 24 hours, target INR 2.0-3.0 1, 8

When to Use Unfractionated Heparin (UFH)

UFH is reserved for patients with severe renal impairment (CrCl <30 mL/min) due to its hepatic clearance and reversibility: 7, 5

• IV UFH: 80 units/kg bolus, then 18 units/kg/hour infusion, adjusted to aPTT ratio 1.5-2.5 5, 9
• Subcutaneous UFH: 333 units/kg load, then 250 units/kg every 12 hours 5, 9

Location-Based Treatment Decisions

Proximal DVT (Popliteal Vein or Above)

• Treat immediately with therapeutic anticoagulation 1, 6, 8
• Home treatment is strongly preferred over hospitalization if home circumstances are adequate, patient is stable, and has access to medications 1, 8

Isolated Distal DVT (Calf Veins Only)

Without severe symptoms or high-risk features:

• Serial imaging surveillance for 2 weeks is preferred over immediate anticoagulation 8
• If thrombus extends to proximal veins on repeat imaging, initiate anticoagulation 8
• If thrombus remains distal but extends, consider anticoagulation 8

With severe symptoms or high-risk features (active cancer, prior VTE, inpatient status, extensive clot burden):

• Initiate therapeutic anticoagulation immediately using same approach as proximal DVT 8

Duration of Anticoagulation

Provoked DVT (Surgery or Major Trauma)

Treat for exactly 3 months, then stop 1, 6, 9

• Strong recommendation against extended therapy beyond 3 months 1, 6

Provoked DVT (Minor Transient Risk Factor)

Treat for 3 months, generally stop 1, 6

• Extended therapy not routinely recommended 1

Unprovoked DVT (No Identifiable Trigger)

• Minimum 3 months of therapeutic anticoagulation required 1, 6, 8
• After 3 months, strongly consider extended anticoagulation (no scheduled stop date) if bleeding risk is low to moderate 1, 6, 2
• Reassess risk-benefit annually 6, 8

Recurrent DVT (≥2 Episodes)

Extended anticoagulation indefinitely (no scheduled stop date) 1, 6, 9

Cancer-Associated DVT

Special considerations apply:

First-line therapy: Oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) are now strongly preferred over LMWH monotherapy 1, 4, 2

LMWH monotherapy remains an option:

• Dalteparin 200 units/kg daily for first month, then 150 units/kg daily 7, 9
• Continue for minimum 3-6 months or as long as cancer is active or patient is receiving chemotherapy 7, 6, 9

Critical caveat: Patients with gastrointestinal malignancies have higher bleeding risk with edoxaban and rivaroxaban compared to LMWH; apixaban or LMWH may be preferred in this subgroup 2

Advanced Therapies

Catheter-Directed Thrombolysis (CDT)

Anticoagulation alone is preferred over CDT for most proximal DVTs 8, 3

Consider CDT only for highly selected patients: 8, 3

• Limb-threatening DVT (phlegmasia cerulea dolens)
• Young patients with iliofemoral DVT at low bleeding risk who strongly value rapid symptom resolution and PTS prevention
• Must have appropriate expertise and resources available

Inferior Vena Cava (IVC) Filters

Do NOT place IVC filters in addition to anticoagulation 8, 2

Place IVC filter ONLY if absolute contraindication to anticoagulation exists (active bleeding, recent neurosurgery, severe bleeding diathesis) 8, 2

Special Populations

Antiphospholipid Syndrome

Use warfarin (target INR 2.0-3.0) over DOACs due to higher failure rates with DOACs in this population 2

Pregnancy

Avoid all DOACs and warfarin 5

• Use LMWH throughout pregnancy and for 6 weeks postpartum 5

Severe Renal Impairment (CrCl <30 mL/min)

Avoid LMWH, fondaparinux, and standard-dose DOACs 7, 5

• Use UFH or dose-adjusted apixaban (2.5 mg twice daily) if appropriate 5

Common Pitfalls to Avoid

• Do not delay anticoagulation while awaiting imaging if clinical suspicion is high and diagnostic testing will be delayed >4 hours 8
• Do not use fondaparinux or LMWH if CrCl <30 mL/min due to drug accumulation and bleeding risk 5
• Do not routinely perform thrombophilia testing—it rarely changes management 10
• Do not hospitalize stable patients with DVT—home treatment is safer and more cost-effective 1, 8
• Do not stop anticoagulation at 6 weeks for proximal DVT—minimum duration is 3 months 1, 6